| scholarly article | Q13442814 |
| P50 | author | Cyrille Hulin | Q40288247 |
| Xavier Leleu | Q40289010 | ||
| Philippe Moreau | Q87734443 | ||
| P2093 | author name string | Jean-Luc Harousseau | |
| Helgi van de Velde | |||
| Milin Acharya | |||
| Valerie Coiteux | |||
| P433 | issue | 12 | |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 1908-1911 | |
| P577 | publication date | 2008-09-02 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma | |
| P478 | volume | 93 |
| Q45328412 | A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation |
| Q48117457 | A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. |
| Q42818861 | Activating transcription factor 4, an ER stress mediator, is required for, but excessive ER stress suppresses osteoblastogenesis by bortezomib |
| Q42361419 | An Overview of Bortezomib-Induced Neurotoxicity |
| Q40261354 | An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes |
| Q33410637 | Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma |
| Q37908155 | Bortezomib for previously untreated multiple myeloma |
| Q37937699 | Bortezomib for previously untreated multiple myeloma |
| Q47604607 | Bortezomib for the treatment of multiple myeloma. |
| Q38096055 | Bortezomib for the treatment of previously untreated multiple myeloma |
| Q99634055 | Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, ran |
| Q88868446 | Clinical Pharmacokinetics and Pharmacodynamics of Bortezomib |
| Q41531584 | Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay |
| Q28244352 | Comparison of distribution and activity of nanoparticles with short interfering DNA (Dbait) in various living systems |
| Q38218209 | Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma. |
| Q38072022 | Current therapeutic strategy for multiple myeloma |
| Q35116018 | Development of a brain metastatic canine prostate cancer cell line. |
| Q38061553 | Effective induction therapy with subcutaneous administration of bortezomib for newly diagnosed POEMS syndrome: a case report and a review of the literature |
| Q38982736 | Effects of the proteasome inhibitor, bortezomib, on cytodifferentiation and mineralization of periodontal ligament cells |
| Q38089497 | Efficacy of bortezomib as first-line treatment for patients with multiple myeloma |
| Q39377326 | Fluorescence-based experimental model to evaluate the concomitant effect of drugs on the tumour microenvironment and cancer cells. |
| Q54575951 | High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib. |
| Q84952811 | Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma |
| Q83425696 | Is subcutaneous bortezomib ready for prime time? |
| Q49989003 | Management of multiple myeloma in the relapsed/refractory patient. |
| Q92276356 | Managing treatment-related peripheral neuropathy in patients with multiple myeloma |
| Q41607725 | Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. |
| Q37017342 | Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials |
| Q41856711 | Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia |
| Q38640514 | Oral ixazomib maintenance therapy in multiple myeloma. |
| Q33443001 | Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. |
| Q90419003 | Patient-Derived Glioma Models: From Patients to Dish to Animals |
| Q37634067 | Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma |
| Q47784917 | Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma |
| Q33442798 | Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma |
| Q87388932 | Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma |
| Q37327280 | Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. |
| Q52822482 | Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors. |
| Q55476988 | Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity. |
| Q35549412 | Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. |
| Q38014395 | Proteasome inhibitors in multiple myeloma: 10 years later |
| Q52637974 | Safety and comfort of domestic bortezomib injection in real-life experience. |
| Q41849927 | Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma |
| Q36138646 | Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial |
| Q33426372 | Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients |
| Q38232055 | Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits |
| Q33422017 | Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy |
| Q64935169 | Subcutaneous bortezomib might be standard of care for patients with multiple myeloma: a systematic review and meta-analysis. |
| Q90733996 | Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis |
| Q33394981 | Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study |
| Q35800851 | Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. |
| Q38164689 | Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences |
| Q89777563 | Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma |
| Q37166798 | The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. |
| Q33787025 | The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients |
| Q88294502 | Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma |
| Q26749180 | Treatment of relapsed and refractory multiple myeloma |
| Q38342281 | Treatment-related symptom management in patients with multiple myeloma: a review |
| Q42559886 | Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib |
Search more.